CompletedInterventionalPhase 3Updated Jun 10, 2009
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration... | NCT00826358 | Trialant
Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg
ClinicalTrials.gov ID
NCT00826358
Lead Sponsor
AstraZenecaINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
90Actual
Last Update Posted
Sep 28, 2012Estimated
Start Date
Nov 2008
Primary Completion Date
Nov 2008Actual
Brief Summary
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.